Eli Lilly has been invested in continuous drug product manufacturing (CM) for over 10 years. Initial efforts focused exclusively on a direct compression platform due to its simplicity and applicability to a large fraction of the portfolio. After realizing the benefits of CM on multiple development and commercial projects, Lilly is expanding its CM footprint to other platforms. This presentation will highlight Lilly's progress in expanding CM capabilities to platforms beyond direct compression.
Learning Objectives:
Upon completion, participants will be able to articulate the value drivers for expanding continuous manufacturing capabilities to maximize its application to the portfolio.
Upon completion, participants will be able to explain the advantages of fluid bed granulation relative to twin screw granulation in a continuous manufacturing process.
Upon completion, participants will be able to discuss possible control strategies for continuous wet granulation processes.
